Skip to main content

Table 5 Univariate associations between demographic, clinical and GA variables and RDI < 85%

From: Association of pre-chemotherapy peripheral blood pro-inflammatory and coagulation factors with reduced relative dose intensity in women with breast cancer

  RDI ≥ 85%
(N = 123) 		RDI < 85%
(N = 36) 		OR (95% CI) P values
Continuous variables     
Age (per year) 56.7 (11.20) 64.2 (11.78) 1.06 (1.02–1.10) 0.001
BMI 29.3 (6.06) 30.4 (7.07) 1.03 (0.97–1.09) 0.363
BSA 1.6 (0.13) 1.6 (0.15) 1.00 (0.06– 5.72) 0.999
Number of comorbidities 1.3 (1.57) 2.3 (2.21) 1.30 (1.06–1.59) 0.01
ADL (MOS physical health) 82.0 (21.30) 70.4 (24.99) 0.98 (0.96–0.99) 0.009
IADL 12.4 (2.84) 11.9 (2.93) 0.95 (0.84–1.07) 0.407
TUG 9.7 (2.23) 9.9 (2.19) 1.04 (0.88–1.22) 0.681
Patient self-rated KPS 90.6 (12.30) 87.2 (15.97) 0.98 (0.96–1.01) 0.185
Physician-rated KPS 95.0 (5.34) 93.5 (7.34) 0.96 (0.90–1.02) 0.184
Number of falls
 0 98 (79.0%) 26 (21.0%) 1.00  
 1+ 23 (69.7%) 10 (30.3%) 1.64 (0.69–3.87) 0.26
Categorical variables     
Race
 Hispanic 33 (82.5%) 7 (17.5%) 1.00  
 Non-Hispanic white 63 (78.8%) 17 (21.3%) 1.27 (0.48–3.38) 0.63
 Asian 10 (66.7%) 5 (33.3%) 2.36 (0.61–9.08) 0.21
 African-American 13 (76.5%) 4 (23.5%) 1.45 (0.36–5.80) 0.60
 Others 3 (50.0%) 3 (50.0%) 4.71 (0.78–28.41) 0.09
 Missing 1    
ER–PR, HER-2 status
 ER+ or PR+, HER2- 83 (78.3%) 23 (21.7%) 1.00  
 HER2+ 17 (68.0%) 8 (32.0%) 1.70 (0.65–4.43) 0.28
 ER- PR- HER2- 23 (82.1%) 5 (17.9%) 0.7 8 (0.27–2.29) 0.66
Stage
 Stage I 27 (79.4%) 7 (20.6%) 1.00  
 Stage II 65 (73.9%) 23 (26.1%) 1.36 (0.52–3.56) 0.52
 Stage III 31 (83.8%) 6 (16.2%) 0.75 (0.22–2.49) 0.63
Chemotherapy regimen
 AC-T 46 (82.1%) 10 (17.9%) 1.00  
 TC 51 (86.4%) 8 (13.6%) 0.72 (0.26–1.98) 0.53
 AC-TH 7 (63.6%) 4 (36.4%) 2.63 (0.64–10.72) 0.18
 TCH 8 (72.7%) 3 (27.3%) 1.73 (0.39–7.68) 0.47
 Sequential A-T-C 4 (40%) 6 (60%) 6.90 (1.64–29.06) 0.009
 Other non-HER2-targeted therapy 4 (66.7%) 2 (33.3%) 2.30 (0.37–14.34) 0.37
 Other HER-2-targeted therapy 3 (50%) 3 (50%) 4.60 (0.81–26.22) 0.09
Anthracycline-containing regimen
 No 61 (81.3%) 14 (18.7%) 1.00  
 Yes 62 (73.8%) 22 (26.2%) 1.55 (0.72–3.30) 0.26
  1. Continuous variables are presented as mean (SD) and categorical variables as N (%)
  2. GA geriatric assessment, RDI reduced dose intensity, BSA body surface area, BMI body mass index, ADL Activities of Daily Living, MOS Medical Outcome Study Physical Heath Scale, IADL Instrumental Activities of Daily Living, TUG Timed Up and Go, KPS Karnofsky Performance Status, TC docetaxel plus cyclophosphamide, AC-T doxorubicin plus cyclophosphamide followed by paclitaxel, TCH docetaxel, carboplatin and trastuzumab, AC-TH doxorubicin plus cyclophosphamide followed by paclitaxel plus trastuzumab, A-T-C sequential doxorubicin, paclitaxel and cyclophosphamide
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us